This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Piñeiro-Carrero, V. M.
Right arrow Articles by Piñeiro, E. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Piñeiro-Carrero, V. M.
Right arrow Articles by Piñeiro, E. O.
Related Collections
Right arrow Therapeutics & Toxicology
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
PEDIATRICS Vol. 113 No. 4 April 2004, pp. 1097-1106


SUPPLEMENT ARTICLE

Liver

Víctor M. Piñeiro-Carrero, MD* and Eric O. Piñeiro, MS{ddagger}

* Alfred I. duPont Hospital for Children, Wilmington, Delaware
{ddagger} Ohio State Environmental Protection Agency, Columbus, Ohio

The liver’s unique metabolism and relationship to the gastrointestinal tract make it an important target of the toxicity of drugs and xenobiotics. The developmental changes that occur in the liver’s metabolic activity from birth to adolescence contribute to the varied sensitivity to toxins seen in the pediatric population. Hepatic drug metabolism, often with an imbalance between the generation of toxic metabolites and detoxification processes, can influence the degree of hepatotoxicity. The decreased capacity of the neonatal liver to metabolize, detoxify, and excrete xenobiotics explains the prolonged action of drugs such as phenobarbital, theophyline, and phenytoin. The reduced capacity of glucuronide conjugation in the neonate not only predisposes them to physiologic jaundice but also is probably responsible for the chloramphenicol-induced gray infant syndrome. Age-related sensitivity to drugs is attributable in part to differences in metabolic activity. For example, young children are more resistant to acetaminophen hepatotoxicity when compared with adults, whereas children are more susceptible to valproic acid–induced toxicity. The resistance to acetaminophen toxicity is attributable to biochemical differences in young children. In children, sulfation predominates over glucuronidation, leading to decreased formation of toxic intermediates. In addition, infants have a greater capacity to synthesize glutathione, thereby inactivating toxic metabolites of acetaminophen more effectively. Hepatic toxicity as a result of drugs and environmental toxins presents a wide spectrum of clinical disease. Hepatitis is the most common presentation, but every major type of liver pathology can occur. Most drug reactions are attributable to idiosyncratic hepatotoxins; therefore, liver injury occurs rarely. The diagnosis of toxin-induced liver disease requires a high index of suspicion and often entails the exclusion of other causes of liver disease in children. Drug or environmental xenobiotic-induced hepatotoxicity should be considered in the setting of identified exposure or when other causes of childhood liver disease are excluded. Children who take medications that are known to be hepatotoxic, such as anticonvulsants and antineoplastic drugs, need frequent monitoring for evidence of hepatic toxicity. The treatment is often nonspecific; the most important intervention is the prompt discontinuation of the drug or removal of the environmental toxin. A specific antidote is available only for acetaminophen intoxication. In cases of severe toxicity, the patient may develop liver failure. Liver transplantation may be necessary for patients whose liver failure does not resolve.


Key Words: hepatotoxicity • xenobiotic • drug metabolism

Abbreviations: CYP, cytochrome P450 • ALT, alanine aminotransferase • AFB, aflatoxin B • ALP, alkaline phosphatase • VOD, veno-occlusive disease • PCB, polychlorinated biphenyl • PCP, pentachlorophenol • TCHQ, tetrachlorohydroquinone


Received for publication Oct 7, 2003; Accepted Oct 20, 2003.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
PediatricsHome page
H. von Rettberg, T. Hannman, U. Subotic, J. Brade, T. Schaible, K. L. Waag, and S. Loff
Use of Di(2-Ethylhexyl)Phthalate-Containing Infusion Systems Increases the Risk for Cholestasis
Pediatrics, August 1, 2009; 124(2): 710 - 716.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
C. E. Rodriguez, D. A. Mahle, J. M. Gearhart, D. R. Mattie, J. C. Lipscomb, R. S. Cook, and H. A. Barton
Predicting Age-Appropriate Pharmacokinetics of Six Volatile Organic Compounds in the Rat Utilizing Physiologically Based Pharmacokinetic Modeling
Toxicol. Sci., July 1, 2007; 98(1): 43 - 56.
[Abstract] [Full Text] [PDF]